Navigation Links
Mirixa Australia Achieves Six Month Milestones
Date:11/17/2009

RESTON, Va. and SYDNEY, Nov. 17 /PRNewswire/ -- Mirixa Corporation, the leader in pharmacy-based patient care services and the Pharmacy Guild of Australia, the peak body representing owners of pharmacies across Australia, announced today results of the first six months of operating activity of Mirixa Australia.

In less than two full quarters of operation, Mirixa Australia has successfully engaged over 40% of all pharmacies nationwide, enabling the delivery of patient care services via the customized Australian version of the MirixaPro(SM) clinical platform.

Mirixa Australia, a subsidiary of the Pharmacy Guild of Australia, now operates patient medication adherence programs, delivered person-to-person at community pharmacy, for both brand and generic medications. Current Australian programs include GSK's Seretide, Pfizer's Lipitor, and generic simvastatin, pravastatin, omeprazole and sertraline medicines offered by Australia's three largest generic medicine distributors, namely Alphapharm, Apotex and Sigma. Programs generally target those patients whose MedsIndex score falls below 70 - an indicator of sub-optimal adherence. The Pharmacy Guild of Australia created and introduced MedsIndex in 2007, and with the help of the Mirixa U.S. team, integrated this score into programs offered through the MirixaPro clinical platform in Australia.

"We're quite proud of what our Australian pharmacy colleagues have accomplished over a very short span of time," said Rick Solano, President and Chief Executive Officer of Mirixa. "The growth rate achieved by Mirixa Australia and its pharmacy partners is truly impressive. They are well on their way to establishing a national pharmacy network to deliver meaningful patient care services similar to what we've achieved here in the U.S.," added Mr. Solano.

Analysis of data by Mirixa Australia across all programs for one of its pilot network pharmacies reveal
'/>"/>

SOURCE Mirixa Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Mirixa Corporation Announces MirixaEdge(SM)
2. Mirixa Corporation Announces Key Pharmacy Network Hire
3. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
4. New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers
5. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
6. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
7. Cepheid GeneXpert(R) System and Xpert(TM) MRSA Selected for up to 11 Victoria, Australia Hospitals in Rollout of Start Clean Strategy
8. New Australian Technology: Detecting Breast Cancer With Hair
9. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
10. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
11. PPD Opens Offices in Sydney, Australia; Copenhagen, Denmark; Lima, Peru; and Lisbon, Portugal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... Feb. 9 Takeda Global ... announced today that it has initiated a trial ... pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics ... has been evaluating all published data and communications ... regarding the potential risks associated with concomitant use ...
(Date:2/9/2010)... 9 DATATRAK International, Inc. (OTCQX: ... global eClinical solutions for the clinical trials industry, ... a CRO Connect Partner, will co-sponsor a seminar ... eClinical solutions for the clinical trials industry. The ... decipher the challenges, costs and obstacles customarily encountered ...
(Date:2/9/2010)... Switzerland , February 9 /PRNewswire/ ... group of companies with,a focus on the ... medical,needs, today announced the signature of an ... manufacture and commercialisation of Debio 025,(alisporivir), a ... anti-hepatitis C virus (HCV) effect. The product ...
Breaking Medicine Technology:Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate) 2Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate) 3Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate) 4DATATRAK International and PFC Pharma Focus to Co-Sponsor eClinical Solutions Seminar in Tel Aviv 2DATATRAK International and PFC Pharma Focus to Co-Sponsor eClinical Solutions Seminar in Tel Aviv 3DATATRAK International and PFC Pharma Focus to Co-Sponsor eClinical Solutions Seminar in Tel Aviv 4Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 2Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 3Reimbursement Difficulties With TranS1s AxiaLIF and NuVasives XLIF Have Sceptics Talking 7074 1Reimbursement Difficulties With TranS1s AxiaLIF and NuVasives XLIF Have Sceptics Talking 7074 2Reimbursement Difficulties With TranS1s AxiaLIF and NuVasives XLIF Have Sceptics Talking 7074 3Accuray Incorporated to Present at 28th Annual J P Morgan Healthcare Conference 7070 1Accuray Incorporated to Present at 28th Annual J P Morgan Healthcare Conference 7070 2HealthWarehouse com Inc Secures 241 Million in Debt Financing 7066 1HealthWarehouse com Inc Secures 241 Million in Debt Financing 7066 2
... therapy reduced risk of breast cancer return or death ... III data to substantiate anticancer effect of Zometa- Zometa ... bone complications due to bone metastases, with more than ... /PRNewswire/ -- A newly published study in ...
... ATLANTA, Feb. 10 Food retailers concerned about pathogens ... coli in their perishable departments can now outsource ... operates food safety and sanitation programs throughout the United ... food safety, Chemstar has expanded its sanitation services to ...
Other Medicine Technology:Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 2Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 3Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 4Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 5Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 6Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 7Chemstar Corporation Offers Comprehensive Deep Cleaning Programs to Combat Salmonella, Listeria, and E. coli in Retail Supermarkets 2
(Date:2/9/2010)... SEATTLE - The incidence of advanced breast cancer diagnosis ... higher compared to white women between 1992 and 2004, ... Cancer Research Center. In addition, the disparity in the ... time period as rates fell among whites but increased ... in the inaugural issue of Springer,s journal Hormones ...
(Date:2/9/2010)... association between television viewing and childhood obesity is directly ... foods, according to a new UCLA School of Public ... Public Health . , The study, conducted by Frederick ... to break down the types of television children watch ... exert different effects on obesity. , The researchers gathered ...
(Date:2/9/2010)... - Overexpression of low-molecular-weight (LMW-E) forms of the ... ineffective among women with estrogen-receptor-positive (ER+) breast cancers, ... Anderson Cancer Center report in Clinical Cancer ... led by Khandan Keyomarsi, Ph.D., professor in M. ... the Hubert L. and Olive Stringer Professor in ...
(Date:2/9/2010)... whacked-out on powerful prescription drugs to treat anxiety disorders. ... sufferer shows natural ways to find relief from constant worry. ... ... -- Over 40 million Americans suffer from anxiety disorders, a ... . Typical anxiety treatment includes prescribing powerful antidepressants or ...
(Date:2/9/2010)... fluoroscopes may increase cancer risk, officials say , ... U.S. Food and Drug Administration unveiled a plan ... of increasingly widespread imaging procedures: computed tomography (CT), ... imaging techniques are the largest contributors to total ... radiation doses than other imaging procedures, such as ...
Breaking Medicine News(10 mins):Health News:Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S. 2Health News:Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S. 3Health News:Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S. 4Health News:Childhood obesity: It's not the amount of TV, it's the number of junk food commercials 2Health News:Low forms of cyclin E reduce breast cancer drug's effectiveness 2Health News:Low forms of cyclin E reduce breast cancer drug's effectiveness 3Health News:Social Anxiety and Panic - Alternative Treatment to Drugs and Therapy 2Health News:FDA Seeks Reduction in Radiation From Medical Scans 2Health News:FDA Seeks Reduction in Radiation From Medical Scans 3
... Company (NYSE: PG ) announced that its Board of ... ($0.35) to forty,cents ($0.40) per share on its Common Stock ... A Preferred Stock of the company, payable on or,after May ... business on,April 18, 2008. This represents a 14% increase compared ...
... To Close Derivative Lawsuit Filed in ... ... April 8, 2008 KV Pharmaceutical,Company (NYSE: KVa/KVb), a fully ... branded and generic/non-branded prescription pharmaceutical,products, announced today that it has ...
... equine estrogen, a commonly prescribed form of estrogen, had ... of benign breast disease as women who took a ... April 8 in the Journal of the National ... estrogen on the risk of developing benign proliferative breast ...
... looking at the spines of hundreds of Finnish twins? If ... Spine Study, you find compelling proof that back pain problems ... , The findings of the Twin Spine Study, an ongoing ... paradigm shift in the way disc degeneration is understood. Last ...
... the worlds busiest ports and shipping regions may be ... study showing that industrial and shipping pollution is exacerbated ... , In a paper published in this weeks advance ... of researchers that included University of Calgary chemistry professor ...
... over $7 million to date in its childhood ... ... In recognition of,national Public Health Week, Anthem Blue Cross, in collaboration ... Index (BMI) training and promotion workshops in Pasadena, San Jose,and Bakersfield, ...
Other Medicine News:Health News:KV Pharmaceutical Company Announces Proposed Settlement in Principle of Derivative Shareholder Litigation 2Health News:KV Pharmaceutical Company Announces Proposed Settlement in Principle of Derivative Shareholder Litigation 3Health News:Estrogen therapy increases benign breast disease risk 2Health News:Award-winning study says back pain may be in your genes 2Health News:Sea salt worsens coastal air pollution: study 2Health News:Anthem Blue Cross Tackles Childhood Obesity in California Through Free BMI Workshops for Pediatric and Family Medicine Health Care Providers 2Health News:Anthem Blue Cross Tackles Childhood Obesity in California Through Free BMI Workshops for Pediatric and Family Medicine Health Care Providers 3
... were designed primarily for schools and laboratories where ... not required. They are constructed to the same ... but have larger tip openings for faster delivery. ... that accuracy tolerances are twice those specified for ...
1000L...
Inquire...
... ergonomics, and value!, Comfortable feel ... non-slip, contoured handle , Finer control ... spring action , Completely autoclavable for ... need for recalibration , Easy-to-read precision ...
Medicine Products: